Drug Profile
Bazedoxifene - Ligand Pharmaceuticals/Pfizer
Alternative Names: Bazedoxifene acetate; Bazedoxifeno; Brilence; Conbriza; TSE-424; Viviant; WAY 140424; WAY-TSE 424Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Ligand Pharmaceuticals; Wyeth
- Developer Almirall S.A.; Ligand Pharmaceuticals; Pfizer
- Class Azepines; Calcium regulators; Indoles; Osteoporosis therapies; Phenols; Small molecules
- Mechanism of Action Selective androgen receptor modulators; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Postmenopausal osteoporosis
- Phase II COVID-19 pneumonia
Most Recent Events
- 19 Jan 2022 Phase-II clinical trials in COVID-19 pneumonia in Czech Republic (Inhalation) (EudraCT2021-005247-78)
- 07 Apr 2015 Bazedoxifene is still in Preregistration for Postmenopausal osteoporosis (Treatment and Prevention) in USA
- 07 Apr 2015 Launched for Postmenopausal osteoporosis in Germany, Lithuania, Sweden, Croatia and Israel (PO) before April 2015